Explore articles tagged with Semaglutide
HRV Pharma's CEO Hari Kiran Chereddi analyzes India's strategic opportunity in GLP-1 drug manufacturing as Semaglutide patents expire in 2026, emphasizing the shift from reverse engineering to innovative design.